Koreas biotech firms strive for growth amid investment challenges at JP Morgan event K-Bio executives highlight new strategies to adapt in a challenging investment landscape at a major healthcare gath ...

Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing ...

SEOUL, South Korea, Jan. 17, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEO James Park) announced on January 16 that it had ...

Local biotech leaders are heading to San Francisco for the 2025 J.P. Morgan Healthcare Conference, one of the industry's biggest annual events. Hotels have been booked, the meetings scheduled and ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of Sherlock Biosciences represents the company's commitment to increase ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

The British pharma giant plans to shell out $1 billion upfront to buy the drug developer working on a lead treatment for gastrointestinal stromal tumors. As the first morning of the J.P. Morgan ...

Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference ... the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days.

Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Ann ...